Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BHV-2100 by Biohaven for Migraine: Likelihood of Approval
BHV-2100 is under clinical development by Biohaven and currently in Phase I for Migraine. According to GlobalData, Phase I drugs...